Danny Sullivan

Glasgow

Contributing Editor at Longevity Technology

Contributing Editor at @LongevityTech. Writer, marketer, PR'er, traveller, reader, runner, technolover and lots of other ers...

Featured in: Favicon

longevity.technology Favicon

flipboard.com

Articles

New longevity fund seeks healthspan-targeting startups

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp A new longevity-focused investment firm has entered the arena, as Seveno Capital officially launched this week. Backed by a $70 million commitment from its founder, entrepreneur Allen Law, the Singapore-based firm is on a mission to invest in early and growth-stage ventures that support the extension of human healthspan.
HepaRegeniX lands €21.5m to advance liver regeneration drug

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp German biotech HepaRegeniX has successfully completed a €21.5 million financing round to advance the clinical development of its lead drug candidate aimed at enhancing liver regeneration in patients with acute and chronic liver conditions. The new investment will specifically be used to finalize the ongoing Phase 1b trial and to initiate and progress a subsequent Phase 2a trial.
Financial firms ‘have a responsibility’ to support longevity innovation

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Last month, financial services giant Manulife announced a new longevity focused initiative with the World Economic Forum, with a focus on addressing the profound demographic shifts occurring across Asia. The “Innovating for Asia’s Demographic Future” challenge seeks to catalyze solutions that enable long-term financial resilience and well-being for individuals as they navigate increasingly multi-stage lives.
Bioniq and Remedy Place team up on personalized supplements

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp After 83% of longevity clinics in our recent survey revealed that they offer their clients guidance on supplementation, personalized supplements company Bioniq has announced a partnership with Remedy Place, which describes itself as the world’s first “social wellness club.” The collaboration merges Bioniq’s AI-powered, blood biomarker-based supplementation system with Remedy’s innovative approach to social wellness, which offers a combination of advanced...
Science Corp lands big funding round to advance BCI technology

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Neurotech firm Science Corporation has reportedly raised more than $100 million in funding led by Khosla Ventures. The company, founded by Neuralink co-founder Max Hodak, is a leading player in the emerging brain-computer interface (BCI) sector.
Does control of proximity equal control of biology?

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Earlier this year, we brought you the story of General Proximity, which emerged from stealth with $16 million to advance the development of next-generation “induced proximity” medicines. The company’s technology leverages the concept of biological proximity – the interaction or nearness of macromolecules – to precisely control molecular interactions.
MYndspan and EMOTIV join forces on brain health

2 weeks ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Brain health tech company MYndspan has announced a strategic investment from wearable neurotech firm EMOTIV as the companies seek to combine their technologies for proactive brain health assessment. The investment comes as MYndspan kicks off a crowdfunding campaign on Crowdcube. MYndspan is a developer of consumer-accessible clinical-grade brain health assessments based on magnetoencephalography (MEG).
Serina raises funding to advance Parkinson's therapy into Phase 1

2 weeks ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp US biotech Serina Therapeutics has announced the completion of a $5 million financing round supported by strategic shareholders to advance its lead clinical candidate into clinical development for the treatment of advanced Parkinson’s disease. The company plans to initiate a Phase 1 clinical trial in the fourth quarter of 2025.
ABL Bio and GSK ink $2.5b neurodegeneration deal

2 weeks ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp South Korean biotech ABL Bio has entered a licensing agreement with pharma giant GSK to develop new treatments for neurodegenerative diseases based on its bispecific antibody technology. The collaboration centers around ABL Bio’s proprietary Grabody-B platform, which is designed to address a key challenge in neurological drug development: the blood-brain barrier.
Neuromodulation system reduces Alzheimer's disease progression by 44%

3 weeks ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp A new paper published in Alzheimer’s Research & Therapy this week highlights the compelling results of a Phase 2 clinical trial evaluating an investigational neuromodulation system for the treatment of Alzheimer’s.